Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026Haemophilia

Extended Half‐Life Recombinant Factor VIII Conjugated with Modifying Substances Does Not Affect Fibrin Clot Formation or Stability in Haemophilia A Blood Samples

View Full Paper
Ask AI
Bookmark
Share

Authors

NSNaruto ShimonishiNara Medical UniversityKNKeiji NogamiNara Medical University

Discussion

Loading...

Member takes

Implication

Randomized trial investigates fibrin clot formation and stability in haemophilia A using modified factor VIII products, suggesting no significant differences in function.

Key Points

  • To determine how modifications to extended half-life recombinant factor VIII affect fibrin clot formation and stability.
  • Evaluated three EHL-FVIII products and two standard FVIII products in FVIII-deficient blood and plasma.
  • Used functional assays including rotational thromboelastometry and microchip flow-chamber analysis.
  • Assessed anticoagulant and fibrinolytic activities through clot waveform analysis.
  • No significant differences in fibrin clot formation and stability among all products at equal activity levels.
  • All products demonstrated comparable anticoagulant and fibrinolytic functions.
  • PEGylation and Fc fusion modifications preserved the functional properties of native FVIII.

Cite This Study

Shimonishi et al. (2026) studied this question.

synapsesocial.com/papers/6a65a890d3aea3239cd78e8chttps://doi.org/10.1111/hae.70361
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip‐based flow chamber system2014 · 34 citations
  2. 2A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process2011 · 97 citations
  3. 3The Importance of Hemostasis on Long-Term Cardiovascular Outcomes in STEMI Patients—A Prospective Pilot Study2025 · 1 citations
  4. 4Impaired factor V–related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations2023 · 13 citations
  5. 5Clot waveform analysis using CS ‐2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A2017 · 54 citations